Apimeds Pharmaceuticals US, Inc. (APUS)
Healthcare · ASE
Price as at 30 Sept 2026, 16:04 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Apimeds Pharmaceuticals US, Inc. trades at $5.00. The share price and the per-share figures behind our estimate for Apimeds Pharmaceuticals US, Inc. appear to be on different share bases, which is what a share split or consolidation looks like before every input has caught up with it. We publish no estimate until the inputs are recomputed on one basis.
Our moat model scores it 5 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
APUS passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
APUS peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- GALDY Galderma Group AG
- JHPCY JHPCY
- HLNCF Haleon plc
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Where does SteadyShares get its APUS data?
Fundamentals for APUS come from company filings and exchange data, as listed on ASE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:04 UTC and is delayed. Our data quality score for this company is 46/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for APUS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.